Corient Private Wealth LLC Has $176 Million Stock Position in Amgen Inc. $AMGN

Corient Private Wealth LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 54.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 537,630 shares of the medical research company’s stock after purchasing an additional 188,531 shares during the quarter. Corient Private Wealth LLC’s holdings in Amgen were worth $176,000,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. lifted its position in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new stake in shares of Amgen during the fourth quarter worth $1,669,000. Adell Harriman & Carpenter Inc. increased its position in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen during the fourth quarter worth $22,441,000. Finally, Sigma Planning Corp raised its stake in Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after buying an additional 3,488 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $337.60 on Friday. The firm has a market capitalization of $182.21 billion, a P/E ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42. The firm’s 50-day moving average price is $340.71 and its 200-day moving average price is $345.76. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the business posted $4.90 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMGN. Leerink Partners reissued a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Truist Financial raised their target price on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Morgan Stanley raised their target price on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Finally, Canaccord Genuity Group began coverage on Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.